New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

A High Rate of Prescriptions Are Written. The Report examined the number of prescriptions that resulted from patient participation in a Program, concluding that the rate was “high”. In one case, the ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

The opportunity to “ talk to a doctor now ” increases access to care, the drug companies say. But the legislators, and some ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth platforms could violate federal anti-kickback laws. The four ...

Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...